About iECURE
iECURE is a company based in Philadelphia (United States) founded in 2020. iECURE has raised $115 million across 2 funding rounds from investors including Orbimed, Novo Holdings and LYFE Capital. The company has 7 employees as of December 31, 2021. iECURE offers products and services including ECUR-506. iECURE operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Philadelphia, United States
- Employees 7 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Iecure, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$115 M (USD)
in 2 rounds
-
Latest Funding Round
$65 M (USD), Series A
Nov 30, 2022
-
Investors
Orbimed
& 3 more
-
Employee Count
7
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of iECURE
iECURE offers a comprehensive portfolio of products and services, including ECUR-506.
In vivo treatment for ornithine transcarbamylase deficiency via gene insertion
People of iECURE
Unlock access to complete
Unlock access to complete
Funding Insights of iECURE
iECURE has successfully raised a total of $115M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $65 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in iECURE
iECURE has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Novo Holdings and LYFE Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
LYFE Capital is recognized as a premier healthcare investment platform.
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked |
Investor details for iECURE
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by iECURE
Investment portfolio details for iECURE
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - iECURE
Detailed financials for iECURE
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iecure Comparisons
Peer comparison for iECURE
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of iECURE
iECURE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of iECURE
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iecure
Complete news archive for iECURE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iECURE
iECURE was founded in 2020 and raised its 1st funding round 1 year after it was founded.
iECURE is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Joseph Truitt is the current CEO of iECURE.
iECURE is a funded company, having raised a total of $115M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at iECURE is 7.
iECURE was founded in 2020 in Philadelphia, United States. Operations center on biotechnology, with an online platform used for genetic engineering in drug development. In vivo gene insertion therapies are developed to address rare pediatric liver diseases, including ARCUS-mediated candidates. Focus remains on therapeutic advancements for these conditions, supported by expertise in gene therapy applications.
iECURE's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
iECURE offers ECUR-506.
iECURE has 4 investors. Key investors include Orbimed, Novo Holdings, LYFE Capital, and Versant Ventures.